Nicotinic receptors and Parkinson's disease

European Journal of Pharmacology

Volumn 393, Issue 1-3, 2000, Pages 223-230

  Quik, Maryka ^a   Jeyarasasingam, Gayathri ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

(Monkey); Hybridization; in situ; MPTP (1 methyl 4 phenyl 1,2,3,6 tetrahydropteridine); Neuroprotection; Nicotinic receptor; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MESSENGER RNA; NEUROTOXIN; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; RECEPTOR SUBUNIT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BASAL GANGLION; BRAIN DEGENERATION; CONFERENCE PAPER; CONTROLLED STUDY; MESENCEPHALON; MONKEY; NERVE CELL CULTURE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BASAL GANGLIA; DOPAMINE AGENTS; DRUG INTERACTIONS; HUMANS; MESENCEPHALON; NEUROPROTECTIVE AGENTS; NICOTINE; PARKINSON DISEASE, SECONDARY; RECEPTORS, NICOTINIC; RNA, MESSENGER; SAIMIRI; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION;

EID: 0034732302     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00888-2     Document Type: Conference Paper

References (89)

1. Agulhon C., Charnay Y., Vallet P., Bertrand D., Malafosse A. Distribution of mRNA for the α4 subunit of the nicotinic acetylcholine receptor in the human fetal brain. Mol. Brain Res. 58:1998;123-131.
2. Akaike A., Tamura Y., Yokota T., Shimohama S., Kimura J. Nicotine induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor mediated glutamate cytotoxicity. Brain Res. 644:1994;181-187.
3. Albuquerque E.X., Alkondon M., Pereira E.F.R., Castro N.G., Schrattenholz A., Barbosa C.T.F., Bonfante-Cabarcas R., Aracava Y., Eisenberg H.M., Maelicke A. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and function. J. Pharmacol. Exp. Ther. 280:1996;1117-1136.
4. Alexander G.M., Brainard D.L., Gordon S.W., Hichens M., Grothusen J.R., Schwartzman R.J. Dopamine receptor changes in untreated and (+)-PHNO treated MPTP parkinsonian primates. Brain Res. 547:1991;181-189.
5. 3H-methylcarbamylcholine in rat brain. Eur. J. Pharmacol. 253:1994;261-267.
6. Arroyo-Jiminez M., Bourgeois J.-P., Marubio L.M., Le Sourd A.-M., Ottersen O.P., Rinvik E., Fairen A., Changeux J.-P. Ultrastructural localization of the α-subunit of the neuronal nicotinic receptor in the rat substantia nigra. J. Neurosci. 19:1999;6475-6487.
7. Aubert I., Araujo D.M., Cecyre D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58:1992;529-541.
8. Balfour D.J.K., Fagerstrom K.O. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol. Ther. 72:1996;51-81.
9. Baron J.A. Cigarette smoking and Parkinson's disease. Neurology. 36:1986;1490-1496.
10. Baron J.A. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br. Med. Bull. 52:1996;58-73.
11. Behmand R.A., Harik S.I. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropteridine neurotoxicity. J. Neurochem. 58:1992;776-779.
12. 125I-α-bungarotoxin binding in human postmortem brain. J. Comp. Neurol. 387:1997;385-398.
13. Carr L.A., Rowell P.P. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine-induced toxicity by cigarette smoke. Neuropharmacology. 29:1990;311-314.
14. Changeux J.-P., Bertrand D., Corringer P.J., Dehaene S., Edelstein S., Lena C., Le Novere N., Marubio L., Picciotto M., Zoli M. Brain nicotinic receptors; structure and regulation, role in learning and reinforcement. Brain. Res. Rev. 26:1998;198-216.
15. Charpantier E., Barneoud P., Moser P., Besnard F., Sgard F. Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantia nigra and ventral tegmental area. NeuroReport. 9:1998;3097-3101.
16. Cimino M., Marini P., Fornasari D., Cattabeni F., Clementi F. Distribution of nAChRs in cynomolgus monkey brain and ganglia: localization of α3 subunit mRNA, α-bungarotoxin and nicotine binding sites. Neuroscience. 51:1992;77-86.
17. Clarke P.B.S., Kumar R. The effects of nicotine on locomotor activity in nontolerant and tolerant rats. Br. J. Pharmacol. 78:1983;329-337.
18. Clarke P.B.S., Pert A. Autoradiographic evidence for nAChRs on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 348:1985;355-358.
19. 125I-α-bungarotoxin. J. Neurosci. 5:1985;1307-1315.
20. Clemens P., Baron J.A., Coffey D., Reeves A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology. 117:1995;253-256.
21. Court J., Clementi F. Distribution of nicotinic subtypes in human brain. Alzheimer Dis. Assoc. Disord. 9(Suppl. 2):1995;6-14.
22. Davila-Garcia M., Houghtling R.A., Qasba S.S., Kellar K. Nicotinic receptor binding sites in rat primary neuronal cells in culture: characterization and their regulation by chronic nicotine. Mol. Brain Res. 66:1999;14-23.
23. Dinely-Miller K., Patrick J. Gene transcripts for the nicotinic acetylcholine receptor subunit beta 4 are distributed in multiple areas of the rat central nervous system. Mol. Brain Res. 16:1992;339-344.
24. Domino E.F., Ni L., Zhang H. Nicotine alone and in combination with L-DOPA methyl ester or the D2 agonist N-0923 in MPTP induced chronic hemiparkinsonian monkeys. Exp. Neurol. 158:1999;414-421.
25. Elliott K.J., Jones J.M., Sacaan A.I., Lloyd G.K., Corey-Naeve J. 6-Hydroxydopamine lesion of the rat nigrostriatal dopaminergic neurons differentially affects nicotinic acetylcholine receptor subunit mRNA. J. Mol. Neurosci. 10:1998;251-260.
26. Fagerstrom K.O., Pomerleau O., Giordani B., Stelson F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology. 116:1994;117-119.
27. Felix R., Levin E.D. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience. 81:1997;1009-1017.
28. Fuxe K., Janson A.M., Jansson A., Andersson K., Eneroth P., Agnati L.F. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and in surviving forebrain dopamine nerve terminal systems after a partial dimesencephalic hemitransection. Naunyn-Schmiedeberg's Arch. Pharmacol. 341:1990;171-181.
29. Gotti C., Fornasari D., Clementi F. Human neuronal nAChRs. Prog. Neurobiol. 53:1997;199-237.
30. Grady S.R., Marks M.J., Collins A.C. Desensitization of nicotine stimulated dopamine release from mouse striatal synaptosomes. J. Neurochem. 62:1994;1390-1398.
31. Grady S.R., Marks M.J., Wonnacott S., Collins A.C. Characterization of nAChR mediated dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59:1992;848-856.
32. Grenhoff J., Janson A.M., Svensson T.H., Fuxe K. Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitransected at the meso-diencephalic junction. Brain Res. 562:1991;347-351.
33. Hadjiconstaninou M., Hubble J.P., Wemlinger T.A., Neff N.H. Enhanced MPTP neurotoxicity after treatment with isofluorophate or cholinergic agonists. J. Pharmacol. Exp. Ther. 270:1994;639-644.
34. Hellenbrand W., Seidler A., Robra B.-P., Vieregge P., Oertel W.H., Joerg J., Nischan P., Schneider E., Ulm G. Smoking and Parkinson's disease: a case control study in Germany. Int. J. Epidemiol. 26:1997;328-339.
35. Irwin I., Delanney L.E., Forno L.S., Finnegan K.T., Di Monte D.A., Langston J.W. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res. 531:1990;242-252.
36. Ishikawa A., Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J. Neurol. Sci. 117:1993;28-32.
37. Janson A.M., Fuxe K., Agnati L.F., Kitayama I., Harfstrand A., Andersson K., Goldstein M. Chronic nicotine treatment counteracts the disappearance of tyrosine hydroxylase immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res. 455:1988;332-345.
38. Janson A.M., Fuxe K., Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropteridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin. Invest. 70:1992;232-238.
39. Janson A.M., Neanna J.J., Goiny M., Herrera-Marschitz M. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the meso-diencephalic junction in rats: a microdialysis study. Neurosci. Lett. 134:1991;88-92.
40. Jeyarasasingam G., Quik M. Nicotinic receptor mediated protection against dopaminergic neuron degeneration in mesencephalic cell cultures. Int. Symp. Nicotine. 3:1999;64.
41. + neurotoxicity in vitro. Neurosci. Abstr. 25:1999;333.
42. Kaneko S., Maeda T., Kume T., Kochiyama H., Akaike A., Shimohama S., Kimura J. Nicotine protects cultured cortical neurons against glutamate induced cytotoxicity via α7 neuronal receptors and neuronal CNS receptors. Brain Res. 765:1997;135-140.
43. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
44. Kilpatrick I., Jones M., Philipson O. A semiautomated analysis method for catecholamines, indoleamines and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem. 46:1986;1865-1876.
45. Lang A.E., Lozano A.M. Parkinson's disease. N. Engl. J. Med. 339:1998;1044-1053.
46. Lang A.E., Lozano A.M. Parkinson's disease. N. Engl. J. Med. 339:1998;1130-1143.
47. Lange K.W., Wells F.R., Jenner P., Marsden C.D. Altered muscarinic and nAChR densities in cortical and subcortical brain regions in Parkinson's disease. J. Neurochem. 60:1993;197-203.
48. Langston J.W., Quik M., Petzinger G., Jakowec M., Di Monte D. Investigating dopa-dyskinesias in the primate model of Parkinson's disease: experimental and methodological considerations. Ann. Neurol. 1999;. in press.
49. Lapin E.P., Maker H.S., Sershen H., Hurd Y., Lajtha A. Dopamine-like action of nicotine: lack of tolerance and reverse tolerance. Brain Res. 407:1987;351-363.
50. Le Novere N., Zoli M., Changeux J.P. Neuronal nAChR α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. J. Neurosci. 8:1996;2428-2439.
51. Li Y., King M.A., Grimes J., Smith N., de Fiebre C.M., Meyer E.M. Alpha 7 nicotinic receptor mediated protection against ethanol-induced cytotoxicity in PC12 cells. Brain Res. 816:1999;225-228.
52. Lichtensteiger W., Hefti F., Felix D., Huwyler T., Melamed E., Schlumpf M. Stimulation of nigrostriatal dopamine neurons by nicotine. Neuropharmacology. 21:1982;963-968.
53. Lindstrom J., Anand R., Gerzanich G., Peng X., Wang F., Wells G. Structure and function of neuronal nicotinic acetylcholine receptors. Prog. Brain Res. 109:1996;125-137.
54. Maggio R., Riva M., Vaglini F., Fornai F., Molteni R., Armogida M., Racagni G., Corsini G.U. Nicotine prevents experimental Parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem. 71:1998;2439-2446.
55. Marin P., Maus M., Desagher S., Glowinski J., Premont J. Nicotine protects cultured striatal against N-methyl-D-aspartate receptor mediated neurotoxicity. NeuroReport. 5:1994;1977-1980.
56. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Heinemann S., Collins A.C. Nicotine binding and nicotine receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 12:1992;2765-2784.
57. Marks M.J., Pauly J.R., Grun E.U., Collins A.C. ST/b and DBA/2 mice differ in brain α-bungarotoxin binding and α7 nicotinic receptor subunit mRNA levels: a quantitative autoradiographic analysis. Mol. Brain Res. 39:1996;207-222.
58. 3H-Acetylcholine and nicotine label the same recognition site in rat brain. Mol. Pharmacol. 31:1987;169-174.
59. Meyer E.M., Li Y., Millard W.J., He Y.J., Papke R. Neuroprotection, neurotoxicity and selective alpha7 nicotinic receptor activation. Neurosci. Abstr. 24:1998;831.
60. Minana M.-D., Montoliu C., Llansola M., Grisolia S., Felipo V. Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology. 37:1998;847-857.
61. Morens D.M., Grandinetti A., Reed D., White L.R., Ross G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue. Neurology. 45:1995;1041-1051.
62. Newhouse P.A., Potter A., Piasecki M., Geelmuyden J., Corwin J., Lenox R. Nicotinic modulation of cognitive functioning in humans. Eff. Nicotine Biol. Syst. II, [Satell. Symp.]. 1995;345-351.
63. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
64. Perry T.L., Hansen S., Jones K. Exposure to cigarette smoke does not decrease neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neurosci. Lett. 74:1987;217-220.
65. Quik M., Jakowec M., Polonskaya Y., Gillespie A., Lloyd G.K., Langston J.W. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. Neurosci. Abstr. 24:1998;1947.
66. Quik M., Philie J., Choremis J. Modulation of alpha 7 nicotinic receptor-mediated calcium influx by nicotinic agonists. Mol. Pharmacol. 51:1997;499-506.
67. Quik M., Polonskaya Y., Gillespie A., Lloyd G.K., Langston J.W. Alterations in nicotinic receptor subunit mRNA levels in monkey brain after MPTP treatment. Neurosci. Abstr. 25:1999;188.
68. Rapier C., Lunt G.G., Wonnacott S. Stereoselective nicotine induced release of dopamine from striatal synaptosomes; concentration dependence and repetitive stimulation. J. Neurochem. 50:1988;1123-1130.
69. Rapier C., Lunt G.G., Wonnacott S. Nicotinic modulation of dopamine release from striatal synaptosomes: pharmacological characterization. J. Neurochem. 50:1990;1123-1130.
70. Riggs J.E. The protective influence of cigarette smoking on Alzheimer's and Parkinson's disease. Quagmire or opportunity for neuroepidemiology? Neuroepidemiology. 14:1996;353-358.
71. Rinne J.O., Myllykyla T., Lonnberg P., Marjamaki P. A postmortem study of brain nAChRs in Parkinson's and Alzheimer's disease. Brain Res. 547:1991;167-170.
72. Role L.W., Berg D.K. NAChRs in the development and modulation of CNS synapses. Neuron. 16:1996;1077-1085.
73. Rubboli F., Court J.A., Sala C., Morris C., Perry E., Clementi F. Distribution of neuronal nAChR subunits in human brain. Neurochem. Int. 25:1994;69-71.
74. Rusted J., Graupner L., Warburton D. Effects of post-trial administration of nicotine on human memory: evaluating the conditions for improving memory. Psychopharmacology. 119:1995;405-413.
75. Schneider J., Pope-Coleman A., Van Velson M., Menzaghi M., Lloyd G.K. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behaviour in parkinsonian monkeys. Mov. Disord. 13:1998;637-642.
76. Schneider J., Van Velson M., Menzaghi M., Lloyd G.K. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys; comparison with levodopa treatment. Ann. Neurol. 43:1998;311-317.
77. Seguela P., Wadiche J., Dinely-Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties and distribution of rat brain α7 receptors: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 13:1993;596-604.
78. Serchen H., Hashim A., Lajtha A. Behavioural and biochemical effects of nicotine in an MPTP induced mouse model of Parkinson's disease. Pharmacol. Biochem. Behav. 28:1987;299-303.
79. Shahi G.S., Das N.P., Moochhala S.M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity; partial protection against striato-nigral dopamine depletion in 57BL/6J mice by cigarette smoke exposure and by β-naphthoflavone-pretreatment. Neurosci. Lett. 93:1991;247-250.
80. Shimohama S., Akaike A., Kimura J. Nicotine induced protection against glutamate cytotoxicity. Ann. N. Y. Acad. Sci. 777:1996;356-361.
81. Sorenson E.M., Shiroyama T., Kitai S.T. Postsynaptic nicotinic receptors on dopaminergic neurons in the substantia nigra pars compacta of the rat. Neuroscience. 87:1998;659-673.
82. Stolerman I.P., Goldfarb T., Fink R., Jarvik M.E. Influencing cigarette smoking with nicotine antagonists. Psychopharmacology. 28:1973;247-259.
83. Tohgi H., Utsugisawa K., Yoshimura M., Nagane Y., Mihara M. Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits α4 and β2 messenger RNA expression in postmortem human putamen. Implications for susceptibility to Parkinsonism. Brain Res. 791:1998;186-190.
84. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., Swanson L.W. Distribution of alpha2, alpha3, alpha4 and beta2 neuronal nAChR subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol. 284:1989;314-335.
85. Wevers A., Sullivan J.P., Giordano T., Birtsch C.H., Monteggia L.M., Nowacki S., Arneric S., Schroder H. Cellular distribution of the mRNA for the α7 subunit of the nicotinic acetylcholine receptor in the human cerebral cortex. Drug Dev. Res. 36:1995;103-110.
86. Winzer-Serhan U.H., Leslie F.M. Codistribution of nAChR subunit α3 and β4 mRNAs during rat brain development. J. Comp. Neurol. 386:1997;540-554.
87. Wonnacott S. Presynaptic nicotinic acetylcholine receptors. Trends Neurosci. 20:1997;92-98.
88. Zamani M.R., Allen Y.S., Owen G.P., Gray J.A. Nicotine modulates the neurotoxic effect of β-amyloid protein (25-35) in hippocampal cultures. NeuroReport. 8:1997;513-517.
89. Zoli M., Le Novere N., Hill J.A., Changeux J.P. Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J. Neurosci. 15:1995;1912-1939.